Charles L. Sawyers, MD, studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the antiandrogen drug enzalutamide, which was approved by the FDA in 2012 for treatment of advanced prostate cancer.
Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985, followed by an internal medicine residency at UCSF. He became a Howard Hughes Medical Institute Investigator in 2002 while at UCLA, then moved to Memorial Sloan Kettering Cancer Center in 2006, where he currently serves as chair of the Human Oncology and Pathogenesis Program.
He shared the 2009 Lasker-DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second generation ABL inhibitor dasatinib to overcome imatinib resistance. He received the 2013 Breakthrough Prize in Life Sciences, the 2013 Taubman Prize for Excellence in Translational Medical Science and the 2015 BBVA Knowledge Award in Biomedicine.
Sawyers is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. He is past President of the American Association for Cancer Research and the American Society of Clinical Investigation, was appointed to the National Cancer Advisory Board by President Obama and has served on the Board of Directors of Novartis since 2013. Read more about his research.
2017 Keynote Presentation
"The Changing Landscape of Cancer Drug Resistance"
Robert H. Lurie Medical Research Building, John Hughes Auditorium
303 E. Superior Street, Chicago
See the entire Research Day schedule.